Search
Desmopressin
go.drugbank.com/drugs/DB00035ApprovedInvestigationalIt is considered a first-line therapy for central diabetes insipidus but is ineffective in patients with nephrogenic diabetes insipidus, where the kidneys are non-responsive to the hormone [A275458, L56105 … First synthesized in the 1960s, desmopressin has remained a gold-standard therapy for water balance disorders due to its safety and long duration of action compared to natural AVP [A31661, A275461].
Antrafenine
go.drugbank.com/drugs/DB01419ApprovedIt is not widely used as it has largely been replaced by newer drugs. … Antrafenine is a piperazine derivative drug that acts as an analgesic and anti-inflammatory drug with similar efficacy to naproxen.
Palonosetron
go.drugbank.com/drugs/DB00377ApprovedInvestigationalAs of 2008, it is the most recent 5-HT3 antagonist to enter clinical use. … HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnIt is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. … Albiglutide was approved on April 15, 2014 by the FDA.
Ondansetron
go.drugbank.com/drugs/DB00904ApprovedInvestigationalWithdrawnand use, including the development of orally soluble films that are both discreet in administration and less of a burden in comparison to having patients attempt to swallow pills during emesis. … Having been developed in the 1980s by GlaxoSmithKline and approved by the US FDA since January 1991, ondansetron has demonstrated a long history of use and efficacy.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: ONDANE, ONDANE 8Testosterone enanthate
go.drugbank.com/drugs/DB13944ApprovedInvestigationalThis slow release is achieved by the presence of the enanthate ester functional group attached to the testosterone molecule. … s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659].
Fosinopril
go.drugbank.com/drugs/DB00492ApprovedInvestigationalFosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals … It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).
Pimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.
Fibrinogen human
go.drugbank.com/drugs/DB09222ApprovedInvestigationalIt works by replacing a specific protein in the blood, fibrinogen (factor I), that helps with blood clotting.
Indapamide
go.drugbank.com/drugs/DB00808ApprovedInvestigational[A204155] Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. … [A204134] When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index
Mixtures: PERINDO/IN RAT T 5/1.25, PERINDO/IN RAT T 5/1.25